ARTICLE
Quviviq vs trazodone — one is approved for insomnia, the other is not
Every other comparison in this cluster is between peers. This one is not: one drug was designed and approved for insomnia, and the other is prescribed for it against guideline advice.
Quviviq (daridorexant) was developed for insomnia, tested for insomnia, and approved by the FDA for insomnia in January 2022. Trazodone was approved for major depressive disorder, and has been prescribed off-label for sleep for decades. That asymmetry is not a technicality. It shapes what evidence exists for each drug, what a prescriber is doing when they choose one, and what you can reasonably expect.
It gets sharper. The American Academy of Sleep Medicine's 2017 pharmacologic guideline does not merely omit trazodone the way it omits Quviviq — it recommends against using it for insomnia. And it is prescribed for sleep constantly anyway, at a small fraction of Quviviq's roughly $500 a month. So the useful question here is not which drug is stronger. It is why that practice persists, and whether it has a logic the trial numbers miss.
| Quviviqdaridorexant | Trazodonegeneric; originally Desyrel | |
|---|---|---|
| FDA-approved indication | Insomnia — approved January 2022 for insomnia characterized by difficulty with sleep onset, sleep maintenance, or both | Major depressive disorder. Not approved for insomnia; sleep use is off-label, and has been for decades |
| Mechanism | Dual orexin receptor antagonist — blocks both OX1 and OX2 to remove the wake signal; does not sedate | 5-HT2A receptor antagonist and serotonin reuptake inhibitor. Unlike benzodiazepines and Z-drugs, which reduce slow-wave activity, trazodone increases slow-wave (deep) sleep |
| Half-life | ~8 hours — short by design, to limit next-day effects | Biphasic: roughly 3–6 hours initial, 5–9 hours terminal — comparable to Quviviq rather than longer. Current FDA labels omit the figure; it comes from the published pharmacokinetics |
| Standard dose for sleep | 25 mg or 50 mg once nightly, within 30 minutes of bed, with at least 7 hours before you plan to wake | 25–100 mg at bedtime, off-label. The approved antidepressant range starts at 150 mg a day and runs to 400 mg for outpatients or 600 mg for inpatients — sleep dosing is a fraction of the approved dose |
| AASM guideline position | Not named — approved five years after the 2017 guideline, so it was never assessed in it | Recommended against: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. [WEAK]" — an objection, not an absence |
| Evidence for insomnia | Two randomized phase 3 trials with insomnia endpoints, supporting the approved indication | One 50 mg trial met the guideline's inclusion criteria: sleep latency −10.2 min, wake after sleep onset −7.7 min, total sleep time +21.8 min, sleep quality −0.13 points — none reaching clinical significance. Polysomnographic meta-analysis is more favorable, showing increased deep sleep and fewer awakenings |
| Next-morning effects | Lower — the short half-life means less drug remaining by morning | Small but significant impairment of short-term memory, verbal learning, equilibrium and arm muscle endurance at 50 mg in a controlled trial. Somnolence was reported by 23% of subjects against 8% on placebo |
| Boxed warning | None | Yes — suicidal thoughts and behaviors in pediatric and young adult patients, the class warning carried by all antidepressants |
| Notable safety concerns | Class cautions: next-day drowsiness, and rare complex sleep behaviors | Priapism — rare, but an erection lasting more than 4 hours means stopping the drug and seeking emergency medical attention. Also orthostatic hypotension and syncope (fall risk in older adults) and QT/QTc prolongation. Taper rather than stopping abruptly |
| Controlled-substance status | Schedule IV | Not a controlled substance |
| Cost & generic availability | No generic — roughly $500 a month | Generic and inexpensive — a small fraction of Quviviq's cost |
One is approved for insomnia. The other is not.
Quviviq's label says insomnia. Daridorexant was developed as an insomnia drug, tested against insomnia endpoints in two randomized phase 3 trials, and approved by the FDA in January 2022 for insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. Whatever else you weigh, the drug was studied for the thing you would be taking it for.
Trazodone's label says major depressive disorder. It says nothing about insomnia, because trazodone was never approved for it. The sleep dose — commonly 25 to 100 mg at bedtime — is not a low version of an approved insomnia dose; it is a fraction of an approved antidepressant dose, which starts at 150 mg a day and runs to 400 mg for outpatients or 600 mg for inpatients. Prescribing it for sleep is off-label, which is legal, common, and entirely within a prescriber's discretion. Off-label is not a scandal. But it does mean nobody was ever required to prove the drug works for this — and largely, nobody has.
That asymmetry explains most of what follows. Approval drives trials, and trials drive guidelines. A drug approved for insomnia accumulates insomnia evidence as a matter of course. A drug used off-label accumulates prescribing habit instead.
What the guideline actually says — and the numbers behind it
The distinction to hold onto is between absence and objection. Quviviq is not named in the AASM's 2017 pharmacologic guideline because it was approved in 2022, five years after that guideline was published — absence there is a date, not a verdict. Trazodone is named. Recommendation 9 reads, in full: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults. [WEAK]" That is a recommendation against. The two situations are categorically different, and treating them as the same would flatter both drugs unfairly.
The evidence behind that recommendation is thin, and it is worth being exact about how thin. One trial met the guideline's inclusion criteria: a single study of trazodone at 50 mg by Walsh and colleagues, with 187 adults across the trazodone and placebo arms, dosed for 14 consecutive nights. Every outcome was patient-reported — there was no polysomnography. In it, sleep latency fell by 10.2 minutes, total sleep time rose by 21.8 minutes, wake after sleep onset fell by 7.7 minutes, and sleep quality moved by −0.13 points on a four-point scale. Not one of those crossed the guideline's threshold for clinical significance, and sleep quality was not significantly improved against placebo at all.
The task force also judged that the harms potentially outweighed the benefits — not because trazodone was shown to be dangerous in that trial, but because there was no demonstrated efficacy on the outcomes that mattered and little systematic information about harms to set against it. "Weak" in the guideline's grading is a statement about confidence rather than force: it means the recommendation could change if better evidence arrives. What it does not mean is that the guideline is neutral on trazodone for sleep. It is not.
So why do doctors still prescribe it?
Because in several specific situations the reasoning is sound. The clearest is comorbid depression. Trazodone is an antidepressant, and if someone has depression and insomnia together — an extremely common pairing — one prescription addressing both is a legitimate clinical choice rather than a shortcut. The guideline's remit was insomnia on its own, not insomnia alongside depression.
The second is patients for whom controlled hypnotics are a poor idea. Trazodone is not a controlled substance and carries none of the dependence profile that makes Z-drugs and benzodiazepines difficult in people with a history of substance use disorder. For that group, a drug with weak efficacy evidence and no misuse potential can genuinely beat a drug with better efficacy evidence and real misuse potential. The third is sleep architecture: where benzodiazepines and Z-drugs suppress slow-wave activity, trazodone increases it. A polysomnographic meta-analysis found more deep sleep and more total sleep time along with fewer awakenings and less wake after sleep onset — a more favorable picture than the single patient-reported trial the guideline had available. And the fourth is cost, which for a great many people decides everything.
The guideline itself concedes the pattern, which is unusual enough to quote. Explaining why it judged that most patients would still choose trazodone over no treatment, the task force wrote that this rests on "the perception of trazodone as a 'safer' sleep-promoting agent by many physicians and the resulting recommendations and prescribing practices of those physicians." Read plainly: the guideline recommends against the drug and, in the same document, acknowledges that physician habit will keep it in use. Both of those are true, and neither cancels the other.
Where the reasoning stops being sound is the default case — trazodone prescribed purely for sleep, to someone with no depression, no substance-use history and no particular cost constraint, because it is simply what gets prescribed. That is the situation Recommendation 9 is aimed at, and it is worth knowing which of these two descriptions is yours.
When Quviviq makes sense
Quviviq's case is straightforward: it is approved for the condition you have, that approval rests on randomized phase 3 trials with insomnia endpoints, and its roughly 8-hour half-life is short by design — daridorexant was engineered to clear quickly, specifically to limit next-day residue. It is dosed at 25 mg or 50 mg once nightly, taken within 30 minutes of bed with at least 7 hours available before you plan to wake. It carries no boxed warning, and across the orexin antagonist class there is little signal of tolerance, dependence, or withdrawal.
The case against it is the price. Roughly $500 a month, no generic, and coverage that many commercial plans decline — which is precisely the gap trazodone fills in practice. If Quviviq is affordable or covered for you, the asymmetry in this comparison runs almost entirely in its favor for insomnia specifically. If it is not, that is a real constraint rather than a failure of will, and it is worth saying out loud to a prescriber rather than quietly not filling the prescription.
The safety picture
Trazodone's next-morning effects are the part most worth knowing, and they are more interesting than the obvious explanation would suggest. In a small randomized trial — 16 people with primary insomnia, taking 50 mg 30 minutes before bed for seven nights — Roth and colleagues measured performance the following morning and found small but significant impairments of short-term memory, verbal learning, equilibrium, and arm muscle endurance. Simulated driving was among the measures taken and was not among the impairments found, which is worth stating precisely rather than rounding up. Sixteen participants is a thin base to reason from, and it deserves the same scepticism this page applies to the efficacy evidence. In the guideline's trial, somnolence was reported by 23% of trazodone subjects against 8% on placebo, and headache by 30% against 19%.
What makes that notable is that trazodone does not linger especially long. Its plasma elimination is biphasic — an initial phase of roughly 3 to 6 hours and a terminal phase of about 5 to 9 hours, comparable to Quviviq's 8 hours rather than longer. So these are not the residue of a long-acting drug; they occur despite a relatively short half-life. Current FDA labels for trazodone do not state a half-life at all, which is its own small illustration of how much of this drug's sleep use rests on literature rather than label.
Three other things belong on the record, stated plainly. Trazodone can cause priapism — a prolonged erection, rare but serious. The label is direct about what to do: an erection lasting more than four hours means stopping the drug and seeking emergency medical attention immediately, whether or not it is painful. It can also cause orthostatic hypotension and syncope, which in older adults translates into fall risk, and it prolongs the QT/QTc interval, which matters if you have a cardiac history or take other QT-prolonging medications. Because it is an antidepressant, it carries the class boxed warning for suicidal thoughts and behaviors in pediatric and young adult patients. And it should be tapered rather than stopped abruptly.
Quviviq's profile is the class profile: Schedule IV, no boxed warning, with next-day drowsiness and rare complex sleep behaviors as the cautions to know. One thing both drugs share is a metabolic pathway — each is cleared through the liver's CYP3A system, so other medications that inhibit or induce it can change how much drug you actually get. The specific label language differs between the two, which is a reason your full medication list belongs in front of the prescriber rather than a rule you can apply for yourself.
The honest part — neither one is a cure
Strip away the asymmetry and both drugs share a limit. Quviviq suppresses a wake signal for one night. Trazodone alters sleep architecture for one night. Neither changes the system generating the insomnia, which is why stopping either tends to return you roughly to where you started — and why the same guideline that recommends against trazodone puts cognitive behavioral therapy for insomnia first for chronic insomnia.
That is not an argument against medication. Pharmacology has a real place, particularly short-term, particularly alongside a behavioral plan, and particularly when depression is part of the picture. It is an argument against expecting a pill to do work it was never capable of. If your nights look like tired but wired — exhausted all day, alert the moment your head hits the pillow — that pattern is the target, and the 6-week program is the structured route at it. The full alternatives map covers what else exists, including the options that are not drugs at all.
Belsomra vs Dayvigo vs Quviviq — the map of the orexin antagonist class, if you have settled on this mechanism and are choosing among the three drugs that use it.
The full Quviviq alternatives guide — the wider map, including the other out-of-class prescription options and why CBT-I remains first-line.
Non-habit-forming sleep aids — the honest guide to what is not a controlled substance, which is the category trazodone belongs to alongside low-dose doxepin.
Quviviq vs Belsomra — the in-class comparison against the first orexin antagonist, and the only one the AASM guideline recommends at all.
Quviviq vs Dayvigo — the in-class comparison where half-life is the deciding factor, shortest against longest.
Quviviq vs Ambien — the cross-class comparison against a Z-drug: generic and cheap, but with a boxed warning and a dependence profile.
The strongest OTC sleep aids, ranked honestly — the pillar guide to the non-prescription landscape, if a milder approach is what you are weighing.
Tired but wired — the hyperarousal pattern that neither of these drugs resolves on its own.
The 6-week program — CBT-I as a structured path, the treatment recommended first-line for chronic insomnia.
Frequently asked questions
Is trazodone better than Quviviq?
For insomnia specifically, the evidence does not support that framing. Quviviq is FDA-approved for insomnia on the strength of two randomized phase 3 trials; trazodone is approved for major depressive disorder, and the AASM's 2017 guideline explicitly recommends against using it for sleep onset or sleep maintenance insomnia. The single 50 mg trial the guideline assessed showed no sleep outcome reaching clinical significance. Where trazodone can be the better choice is when the whole clinical picture, not just the insomnia, is taken into account — someone with depression alongside their insomnia, someone for whom a controlled substance is a poor idea, or someone for whom roughly $500 a month is simply not possible. These two drugs have never been compared head-to-head, so nobody can offer you a direct ranking. The comparison belongs with a prescriber who knows your history.
Why do doctors prescribe trazodone for sleep if it's not approved for it?
Off-label prescribing is legal and routine: once a drug is approved for anything, a physician may prescribe it for something else based on clinical judgment. With trazodone there are real reasons behind the habit. It is not a controlled substance, so it carries none of the dependence and misuse concerns that make Z-drugs and benzodiazepines difficult for some patients. It treats depression, which frequently accompanies insomnia. It increases slow-wave sleep, where the older sedatives suppress it. And it is generic and cheap. The AASM guideline actually acknowledges this pattern in its own text — it notes that most patients would likely still use trazodone, based on "the perception of trazodone as a 'safer' sleep-promoting agent by many physicians and the resulting recommendations and prescribing practices of those physicians." The guideline recommends against the drug and concedes that habit will keep it in use.
Is trazodone habit forming?
Trazodone is not a controlled substance and does not carry the dependence and misuse profile of benzodiazepines or Z-drugs, which is a large part of why it is prescribed for sleep as often as it is. That is not the same as being able to stop it whenever you like. It is an antidepressant, and antidepressants should be tapered rather than discontinued abruptly — the label says to reduce the dosage gradually wherever possible. So the accurate answer is that trazodone is not habit forming in the addiction sense, but stopping it is still a conversation to have with your prescriber rather than a decision to make on your own one evening.
Can you switch from trazodone to Quviviq?
Switching between them is a normal clinical conversation, but it is not a simple swap, and there are two specific reasons it needs a prescriber. First, trazodone is an antidepressant: if you are taking it for depression as well as sleep — or if it is quietly doing some work on your mood that neither of you has fully accounted for — stopping it removes that, and Quviviq does nothing for depression. Second, it should be tapered rather than stopped abruptly. Cost is a legitimate reason to want the switch in either direction, as are poor results or next-morning grogginess. Bring the reason to the prescriber and let them manage the taper and the timing.
How much cheaper is trazodone than Quviviq?
Substantially, and for many people this is the factor that decides. Quviviq runs roughly $500 a month, has no generic, and is frequently not covered — daridorexant remains under patent. Trazodone has been generic for many years and is among the less expensive prescriptions in common use. A precise multiplier is not worth quoting, because generic pricing varies widely by pharmacy, plan, and discount program, so the number you would actually pay is worth checking directly rather than taking from an article. The honest summary is that the gap is large enough that cost alone can reasonably drive the decision — which is worth saying to your prescriber directly, because it is a clinical fact about your situation rather than an embarrassment.
Sources
- U.S. Food and Drug Administration (FDA) — Prescribing Information for QUVIVIQ (daridorexant), Idorsia Pharmaceuticals: the approved insomnia indication, dual orexin receptor antagonism, Schedule IV status, ~8-hour half-life, 25 mg / 50 mg dosing within 30 minutes of bed with at least 7 hours before awakening, CYP3A metabolism, and class warnings (next-day somnolence, complex sleep behaviors).
- U.S. Food and Drug Administration (FDA) — Prescribing Information for trazodone hydrochloride tablets: the major depressive disorder indication (insomnia is not an approved indication), the 150 mg starting dose with 400 mg outpatient and 600 mg inpatient maximums, the boxed warning for suicidal thoughts and behaviors in pediatric and young adult patients, the priapism warning (erection lasting more than 4 hours — discontinue and seek emergency medical attention), orthostatic hypotension and syncope, QT/QTc prolongation, CYP3A4 metabolism and interaction guidance, and the instruction to reduce the dosage gradually rather than stopping abruptly.
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349. Source for Recommendation 9 against trazodone, the single 50 mg trial it rests on, the patient-reported outcome figures (sleep latency −10.2 min, total sleep time +21.8 min, WASO −7.7 min, sleep quality −0.13 points), the harms data, and the task force's remarks on physician prescribing practices. Also the source for CBT-I as first-line treatment for chronic insomnia.
- Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13(3):191–198. The single trazodone 50 mg trial assessed in the AASM guideline: 187 adults across the trazodone and placebo arms, 14 consecutive nights, all outcomes patient-reported.
- Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20(4):552–558. A within-subjects, randomized, double-blind, placebo-controlled study in 16 primary insomniacs at 50 mg: small but significant impairment of short-term memory, verbal learning, equilibrium and arm muscle endurance the following morning, with greater slow-wave sleep than placebo on day 7.
- De Crescenzo F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–184.
- Zheng Y, et al. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Sci Rep. 2022;12:14453. Source for the polysomnographic picture: increased total sleep time and slow-wave (N3) sleep, with reductions in wake after sleep onset and number of awakenings.
- Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139.